GSK readying Ebola vax; Former FDA critic now big supporter; Pfizer fights Benadryl price cut in India;

@FiercePharma: Top-read on FP this weekend: Pfizer faces growing legal threat over Lipitor. Article | Follow @FiercePharma

@EricPFierce: ICYMI last week: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: Favorite fact I've learned so far today: The inhaler for MannKind's Afrezza inhaler is named "Dreamboat." | Follow @CarlyHFierce

> The FDA has approved Johnson & Johnson's ($JNJ) Invokamet, a combination of its diabetes drug Invokana and metformin. Story

> Vax leader GlaxoSmithKline ($GSK) says it will soon start a clinical trial for a vaccine for the lethal Ebola virus. Story

> Cubist Pharmaceuticals ($CBST) has expanded its recall of anti-infection drug Cubicin to 9 lots because of particulate matter found in some vials. Release

> Gregg Gonsalves, who was a big critic of the FDA in the 1990s in his fight for drugs to treat AIDS, is now defending the agency against what he considers anti-regulatory sentiment. Story

Medical Device News

@FierceMedDev: ICYMI: Volcano guides lower but offers long-term vision, Wall Street trims by as much as 25%. Article | Follow @FierceMedDev

@StacyALawrence: Med tech M&A gets much, much bigger during the first half. Feature | Follow @StacyALawrence

@VarunSaxena2: RT @foodanddruglaw: CMS delays launch of Sunshine Act reporting website. More from The Hill | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Not for the faint of heart: A behind-the-scenes look at creating prosthetic eyes. More from NPR | Follow @EmilyWFierce

> Medtronic hires former senators to lobby against anti-inversion bill and protect acquisition of Covidien. Report

> Imaging pen may detect skin cancer faster. More

Biotech News

@FierceBiotech: Can GlaxoSmithKline go from 0 to 150 on an Ebola vaccine program? Story | Follow @FierceBiotech

@JohnCFierce: ICYMI last week: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. More | Follow @JohnCFierce

@DamianFierce: $MNKD finally gets its Afrezza deal as $SNY signs up for $150M up front and $775M in milestones. Article | Follow @DamianFierce

> Forward Pharma sets sights on Biogen with a $200M IPO. Article

> J&J's diabetes combo wins FDA nod in a fast-crowding space. News

> Google sheds glancing light on Calico, its anti-aging biotech. More

CRO News

> Icon charts another sales jump with eyes on a big year. Report

> Charles River's checkbook fuels a leap in revenue. More

> Quintiles and Roche take to China with testing partnership. News

> Parexel notches double-digit annual growth with a big year ahead. Article

> Deal-minded Venn buys another CRO. Story

Biotech IT News

> Actelion working with PatientsLikeMe rare cancer community on outcome measure. Report

> U.S. research institutes target standard neuroscience data format. More

> AllSeq, DNAnexus share data from Illumina HiSeq X Ten. Story

> Google rolls out preview of healthcare app development kit. Article

> The race to build a robo-chemist. Item

Animal Health News

> Cost spike of doxycycline has created sticker shock for pet owners. Report

> Zoetis CEO sees global factors coalescing to spur more growth. More

> Medical marijuana coming to the pet med market. Item

> SmartPak acquisition helps Henry Schein grow its animal health sales. Story

> Zoetis expects to have PEDv vaccine ready this year. Article

And Finally... The fight over the price Pfizer ($PFE) can charge in India for its popular cough syrup Benadryl continues. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…